Desmoglein as a target in autoimmunity and infection

Journal of the American Academy of Dermatology

Volumn 48, Issue 2 SUPPL., 2003, Pages 244-252

  Amagai, Masayuki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1; EXFOLIATIN;

ARTICLE; AUTOIMMUNITY; BLISTER; CELL ADHESION; DESMOSOME; HUMAN; IMMUNOCHEMISTRY; MOLECULAR MECHANICS; PEMPHIGUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STRUCTURE ANALYSIS; TOXIC EPIDERMAL NECROLYSIS;

EID: 0037323410     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.7     Document Type: Article

References (61)

1. Green KJ, Gaudry CA. Are desmosomes more than tethers for intermediate filaments? Nat Rev Mol Cell Biol 2000;1:208-16.
2. Gorbsky G, Steinberg MS. Isolation of the intercellular glycoproteins of desmosomes. J Cell Biol 1981;90:243-8.
3. Cowin P, Mattey D, Garrod D. Identification of desmosomal surface components (desmocollins) and inhibition of desmosome formation by specific Fab'. J Cell Sci 1984;70:41-60.
4. Schwarz MA, Owaribe K, Kartenbeck J, Franke WW. Desmosomes and hemidesmosomes: constitutive molecular components. Annu Rev Cell Biol 1990;6:461-91.
5. von Rittershain GR. Die exfolitive dermatitis jungener senglinge. Z Kinderheilkd 1878;2:3-23.
6. Yokota S, Imagawa T, Katakura S, Mitsuda T, Arai K. Staphylococcal scalded skin syndrome caused by exfoliative toxin B-producing methicillin-resistant Staphylococcus aureus. Eur J Pediatr 1996;155:722.
7. Acland KM, Darvay A, Griffin C, Aali SA, Russell-Jones R. Staphylococcal scalded skin syndrome in an adult associated with methicillin-resistant Staphylococcus aureus. Br J Dermatol 1998;140:518-20.
8. Melish ME, Glasgow LA. The staphylococcal scalded skin syndrome: development of an experimental model. N Engi J Med 1970;282:1114-9.
9. Kondo I, Sakurai S, Sarai Y. New type of exfoliation obtained from staphylococcal strains, belonging to phage groups other than group II, isolated from patients with impetigo and Ritter's disease. Infect Immun 1974;10:851-61.
10. Lillibridqe CB, Melish ME, Glasgow LA. Site of action of exfoliative toxin in the staphylococcal scaled-skin syndrome. Pediatrics 1972;50:728-38.
11. Melish ME, Glasgow LA, Turner MD, Lillibridge CB. The staphylococcal epidermolytic toxin: its isolation, characterization, and site of action. Ann N Y Acad Sci 1974;236:317-42.
12. Elias PM, Fritsch P, Dahl MV, Wolff K. Staphylococcal toxic epidermal necrolysis: pathogenesis and studies on the subcellular site of action of exfoliation. J Invest Dermatol 1975;65:501-12.
13. Dimond RL, Wolff HH, Braun-Falco O. The staphylococcal scalded skin syndrome: an experimental histochemical and electron microscopic study. BrJ Dermatol 1977;96:483-92.
14. O'Toole PW, Foster TJ. Molecular cloning and expression of the epidermolytic toxin A gene of Staphylococcus aureus. Microb Pathog 1986;1:583-94.
15. Lee CY, Schmidt JJ, Johnson-Winegar AD, Spero L, landolo JJ. Sequence determination and comparison of the exfoliative toxin A and toxin B genes from Staphylococcus aureus. J Bacteriol 1987;169:3904-9.
16. Kappler J, Kotzin B, Herron L,Gelfand EW, Bigler RD, Boylston A, et al. V beta-specific stimulation of human T cells by staphylococcal toxins. Science 1989;244:811-3.
17. Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. Proc Natl Acad Sci U S A 1989;86:8941-5.
18. Fleischer B, Bailey CJ. Recombinant epidermolytic (exfoliative) toxin A of Staphylococcus aureus is not a superantigen. Med Microbiol Immunol (Berl) 1992;180:273-8.
19. Fleischer B, Gerlach D, Fuhrmann A, Schmidt KH. Superantigens and pseudosuperantigens of gram-positive cocci. Med Microbiol Immunol (Berl) 1995;184:1-8.
20. Plano LR, Gutman DM, Woischnik M, Collins CM. Recombinant Staphylococcus aureus exfoliative toxins are not bacterial superantigens. Infect Immun 2000;68:3048-52.
21. Vath GM, Earhart CA, Rago JV, Kim MH, Bohach GA, Schlievert PM, et al. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 1997;36:1559-66.
22. Cavarelli J, Prevost G, Bourguet W, Moulinier L, Chevrier B, Delagoutte B, et al. The structure of Staphylococcus aureus epidermolytic toxin A, an atypic serine protease, at 1.7 A resolution. Structure 1997;5:813-24.
23. Vath GM, Earhart CA, Monie DD, landolo JJ, Schlievert PM, Ohlendorf DH. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity. Biochemistry 1999;38:10239-46.
24. Beutner EH,Jordon RE. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964;117:505-10.
25. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976;67:254-60.
26. Farb RM, Dykes R, Lazarus GS. Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. Proc Natl Acad Sci U S A 1978;75:459-63.
27. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982;306:1189-96.
28. Stanley JR, Yaar M, Hawley NP, Katz SI. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest 1982;70:281-8.
29. Hashimoto T, Ogawa MM, Konohana A, Nishikawa T. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol 1990;94:327-31.
30. Stanley JR, Koulu L, Thivolet C. Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies. J Clin Invest 1984;74:313-20.
31. Eyre RW, Stanley JR. Human autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients. J Exp Med 1987;165:1719-24.
32. Koulu L, Kusumi A, Steinberg MS, Klaus-Kovtun V, Stanley JR. Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J Exp Med 1984;160:1509-18.
33. Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J Immunol 1986;136:1227-30.
34. Koch PJ, Walsh MJ, Schmelz M, Goldschmidt MD, Zimbelmann R, Franke WW. Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. Eur J Cell Biol 1990;53:1-12.
35. Goodwin L, Hill JE, Raynor K, Raszi L, Manabe M, Cowin P. Desmoglein shows extensive homology to the cadherin family of cell adhesion molecules. Biochem Biophys Res Commun 1990;173:1224-30.
36. Nilles LA, Parry D, Powers EE, Angst BD, Wagner RM, Green KJ. Structural analysis and expression of human desmoglein: a cadherin-like component of the desmosome. J Cell Sci 1991;99:809-21.
37. Wheeler GN, Parker AE, Thomas CL, Ataliotis P, Poynter D, Arnemann J, et al. Desmosomal glycoprotein DGI, a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion molecules. Proc Natl Acad Sci U S A 1991;88:4796-800.
38. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67:869-77.
39. Buxton RS, Cowin P, Franke WW, Garrod DR, Green KJ, King IA, et al. Nomenclature of the desmosomal cadherins. J Cell Biol 1993;121:481-3.
40. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
41. Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K, Takeichi M. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 1987;329:341-3.
42. Amagai M, Fujimori T, Masunaga T, Shimizu H, Nishikawa T, Shimizu N, et al. Delayed assembly of desmosomes in keratinocytes with disrupted classic cadherin-mediated cell adhesion by a dominant negative mutant. J Invest Dermatol 1995;104:27-32.
43. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-26.
44. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994;94:59-67.
45. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995;104:895-901.
46. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmogleinl. J Invest Dermatol 1998;110:76-8.
47. Mahoney MG, Wang Z, Rothenberger KL, Koch PJ, Amagai M, Stanley JR. Explanation for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-8.
48. Udey MC, Stanley JR. Pemphigus-diseases of antidesmosomal autoimmunity. JAMA 1999;282:572-6.
49. Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 1999;20:92-102.
50. Ding X, Aoki V, Mascaro JM, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997;109:592-6.
51. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167-70.
52. Harman K, Gratian M, Bhogal B, Challacombe S, Black M. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 2000;143:343-8.
53. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (Desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996;106:351-5.
54. Wu H, Wang ZH, Yan A, Lyle S, Fakharzadeh S, Wahl JK, et al. Protection against pemphigus foliaceus by desmoglein 3 in neonates. N Engl J Med 2000;343:31-5.
55. Chowdhury MM, Natarajan S. Neonatal pemphigus vulgaris associated with mild oral pemphigus vulgaris in the mother during pregnancy. Br J Dermatol 1998;139:500-3.
56. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded skin syndrome targets desmoglein 1. Nat Med 2000;6:1275-7.
57. Amagai M, Yamaguchi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 2002;118:845-50.
58. Yamaguchi T, Nishifuji K, Sasaki M, Fudaba Y, Aepfelbacher M, Takata T, et al. Identification of Staphylococcus aureus etd pathogenicity island which encodes a novel exfoliative toxin, ETD, and EDIN-B. Infect Immunity 2002;70:5835-45.
59. Hanakawa Y, Schechter NM, Lin C, Garza L, Li H, Yamaguchi T, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002;110:53-60.
60. Takagi Y, Futamura S, Asada Y. Action site of exfoliative toxin on keratinocyte. J Invest Dermatol 1990;94:582a.
61. Proby CM, Ohta T, Suzuki H, Koyasu S,Gamou S, Shimizu N, et al. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol 2000;142:321-30.